Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Vaccines

Free Subscription Articles published in Virus Res Retrieve available abstracts of 29 articles: HTML format

Single Articles

April 2026
1. FARSIU N, Mahani FK, Arefinia N, Charostad J, et al
   From Legacy to Innovation: A Comprehensive Review of Vaccine Platforms Against Viral Infections.
   Virus Res. 2026 Apr 16:199730. doi: 10.1016/j.virusres.2026.199730.
   PubMed     Abstract available
   
   
   
2. XU M, Zhang C, Liu Y, Chen S, et al
   Corrigendum to"A noval strategy of deletion in PK gene for construction of a vaccine candidate with exellent safety and complete protection efficiency against high virulent Chinese pseudorabies virus variant" [Virus Research 313 (2022) 198740].
   Virus Res. 2026 Apr 8:199719. doi: 10.1016/j.virusres.2026.199719.
   PubMed    
   
   
   
3. WU Y, Sun W, Xia Y, Feng Y, et al
   The influenza B virus candidate vaccine expressing H3 hemagglutinin developed in suspension MDCK cells confers protection against lethal H3N2 avian influenza in BALB/c mice.
   Virus Res. 2026;367:199722.
   PubMed     Abstract available
   
   
   
4. SITHOLE MN, Khan MR, Mohammed HA, Khan RA, et al
   A Systematic Review on Vaccine Developmental Approaches: Evaluating Efficacy, and Addressing Challenges of Infectious Diseases in the Post-COVID-19 Era.
   Virus Res. 2026 Apr 1:199720. doi: 10.1016/j.virusres.2026.199720.
   PubMed     Abstract available
   
   
   March 2026
5. YUNUS AO, Olanrewaju OA
   Fractional-order Modeling of Vaccination Strategies for Measles Transmission Incorporating Immune Memory.
   Virus Res. 2026 Mar 28:199718. doi: 10.1016/j.virusres.2026.199718.
   PubMed     Abstract available
   
   
   February 2026
6. LUO X, Liu H, Kuang H, Xie Y, et al
   Impacts of Delayed Influenza Vaccination on Clinical Outcomes in ICU-Admitted Patients with Influenza: A Retrospective Cohort Study.
   Virus Res. 2026 Feb 3:199700. doi: 10.1016/j.virusres.2026.199700.
   PubMed     Abstract available
   
   
   January 2026
7. NAZKI S, Reine J, Kailath R, Gilbert S, et al
   Replication-incompetent viral vaccine vectors ChAdOx1 and MVA as tools for evaluating T-cell responses to naturally processed antigens in vitro.
   Virus Res. 2026;364:199691.
   PubMed     Abstract available
   
   
   
8. NGUYEN TTN, Tun MMN, Vu TBH, Nguyen TTT, et al
   Implications of Immune Responses to DENV, JEV, and ZIKV Infections for Cross-Reactivity and Considerations for Vaccine Evaluation.
   Virus Res. 2026 Jan 8:199689. doi: 10.1016/j.virusres.2026.199689.
   PubMed     Abstract available
   
   
   December 2025
9. KWAN E, Legione AR, Hartley CA, Devlin JM, et al
   Transcriptomic analysis of Crandell-Rees feline kidney cell infections with field and vaccine feline calicivirus strains.
   Virus Res. 2025 Dec 21:199681. doi: 10.1016/j.virusres.2025.199681.
   PubMed     Abstract available
   
   
   
10. IANKOV I, Ammayappan A, Viker K, Weisend C, et al
    Replication competent La Crosse virus pseudotyped VSV vector system as vaccine and serological diagnostic reagent.
    Virus Res. 2025 Dec 15:199676. doi: 10.1016/j.virusres.2025.199676.
    PubMed     Abstract available
    
    
    November 2025
11. KHAN A, Mohammad A, Alshabrmi FM, Alatawi EA, et al
    HMPV-TherResDB: Comprehensive Human Metapneumovirus (HMPV) Database for Sequence-Structure Annotations, Vaccine Resources, and Therapeutics Research.
    Virus Res. 2025 Nov 16:199665. doi: 10.1016/j.virusres.2025.199665.
    PubMed     Abstract available
    
    
    
12. CAO W, Li J, Yang F, Zhu Z, et al
    Comparative investigation into the immune efficiency of the single intradermal and intramuscular delivery of foot-and-mouth disease inactivated vaccine in swine.
    Virus Res. 2025 Nov 3:199656. doi: 10.1016/j.virusres.2025.199656.
    PubMed     Abstract available
    
    
    September 2025
13. VOKO Z, Turi G, Oroszi B, Belicza E, et al
    Association between COVID-19 vaccination and progression to severe outcomes in hospitalized COVID-19 patients in Hungary during the pre-Omicron era of the COVID-19 pandemic.
    Virus Res. 2025;361:199633.
    PubMed     Abstract available
    
    
    July 2025
14. MARTINEZ ES, Fuchs S, Szurmant H, Chen X, et al
    COVID-19 mRNA vaccine immune response to the addition of osteopathic manipulative treatment with lymphatic pumps: a randomized controlled trial.
    Virus Res. 2025 Jul 14:199607. doi: 10.1016/j.virusres.2025.199607.
    PubMed     Abstract available
    
    
    June 2025
15. YANG K
    Accelerating Vaccine Development: Plug-and-Play Platforms for Emerging Infectious Diseases.
    Virus Res. 2025 Jun 21:199601. doi: 10.1016/j.virusres.2025.199601.
    PubMed     Abstract available
    
    
    
16. LI H, Han J, Wang B, Han Z, et al
    Isolation and characterization of GI-19/L1148-like infectious bronchitis virus in China.
    Virus Res. 2025;356:199576.
    PubMed     Abstract available
    
    
    April 2025
17. MATHUR G, Mahilkar S, Sunil S
    Generation and characterization of infectious clones of chikungunya virus from an Indian strain as a resource towards chikungunya vaccine research.
    Virus Res. 2025;356:199571.
    PubMed     Abstract available
    
    
    March 2025
18. MYERS ML, Conlon MT, Gallagher JR, Woolfork DD, et al
    Analysis of polyclonal and monoclonal antibody to the influenza virus nucleoprotein in different oligomeric states.
    Virus Res. 2025 Mar 24:199563. doi: 10.1016/j.virusres.2025.199563.
    PubMed     Abstract available
    
    
    January 2025
19. RAHMAN MA, Zereen F, Rana ML, Hossain MG, et al
    Foot-and-mouth disease in Asia.
    Virus Res. 2025;351:199514.
    PubMed     Abstract available
    
    
    December 2024
20. GIRMA A
    Biology of human respiratory syncytial virus: Current perspectives in immune response and mechanisms against the virus.
    Virus Res. 2024;350:199483.
    PubMed     Abstract available
    
    
    
21. LU H, Shao J, Liu W, Gao S, et al
    Screening and identification of linear B-cell epitopes on structural proteins of African Swine Fever Virus.
    Virus Res. 2024;350:199465.
    PubMed     Abstract available
    
    
    October 2024
22. CHEN J, Cheng Z, Chen J, Qian L, et al
    Advances in human norovirus research: Vaccines, genotype distribution and antiviral strategies.
    Virus Res. 2024;350:199486.
    PubMed     Abstract available
    
    
    September 2024
23. CHEN Y, Tang Y, Zhang S, Tian Y, et al
    Evaluation of novel synthetic peptides of avian hepatitis E virus ORF2 as vaccine candidate in chickens.
    Virus Res. 2024 Sep 3:199459. doi: 10.1016/j.virusres.2024.199459.
    PubMed     Abstract available
    
    
    July 2024
24. ZHANG G, Peng Q, Liu S, Fan B, et al
    The glycosylation sites in RBD of spike protein attenuate the immunogenicity of PEDV AH2012/12.
    Virus Res. 2024;345:199381.
    PubMed     Abstract available
    
    
    June 2024
25. SPEDICATO M, Ronchi GF, Profeta F, Traini S, et al
    Efficacy of an inactivated EHDV-8 vaccine in preventing viraemia and clinical signs in experimentally infected cattle.
    Virus Res. 2024 Jun 17:199416. doi: 10.1016/j.virusres.2024.199416.
    PubMed     Abstract available
    
    
    
26. JALILVAND S, Latifi T, Kachooei A, Mirhoseinian M, et al
    Circulating rotavirus strains in children with acute gastroenteritis in Iran, 1986 to 2023 and their genetic/antigenic divergence compared to approved vaccines strains (Rotarix, RotaTeq, ROTAVAC, ROTASIIL) before mass vaccination: Clues for vaccinatio
    Virus Res. 2024;346:199411.
    PubMed     Abstract available
    
    
    May 2024
27. LIN X, Yang F, Yan S, Wu H, et al
    Preparation and characterization of mouse-derived monoclonal antibodies against the hemagglutinin of the H1N1 influenza virus.
    Virus Res. 2024;345:199402.
    PubMed     Abstract available
    
    
    April 2024
28. WANG Z, Sun W, Li D, Sun Y, et al
    A live attenuated influenza B virus vaccine expressing RBD elicits protective immunity against SARS-CoV-2 in mice.
    Virus Res. 2024;345:199378.
    PubMed     Abstract available
    
    
    
29. AVIZINIENE A, Dalgediene I, Armalyte J, Petraityte-Burneikiene R, et al
    Immunogenicity of Novel vB_EcoS_NBD2 Bacteriophage-Originated Nanotubes as a Carrier for Peptide-Based Vaccines.
    Virus Res. 2024 Apr 11:199370. doi: 10.1016/j.virusres.2024.199370.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Vaccines is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum